clinical trial · NCT07256015
Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy
Bristol-Myers Squibb·—·active not recruiting·n = 200
PsoriasisDeucravacitinib
brief summary
The purpose of this study is to characterize the real-life experience of patients with moderate/severe psoriasis receiving deucravacitinib treatment, in terms of efficacy, safety, and health-related quality of life (HRQoL) in Italy
started
Aug 5, 2025
primary completion
Jul 5, 2027
completion
Aug 5, 2027
last updated
Nov 2, 2026
official title
"DEMOS" - Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol